期刊文献+

米多君治疗女性压力性尿失禁的临床和尿动力学研究 被引量:4

Clinical and urodynamic study of midodrine in treatment of female stress urinary incontinence
下载PDF
导出
摘要 目的:观察米多君治疗女性压力性尿失禁(SUI)的临床效果和尿动力学变化。方法:19例SUI病人予米多君2.5 mg,po,tid,疗程4 wk。观察治疗前后尿失禁等级评分(MHU)、尿失禁自我评价(ICIQ)和尿动力学检查结果。结果:19例病人治疗前后临床有效率74%(14/19);主观症状ICIQ评分和MHU评分均明显下降,差异有非常显著意义(P<0.01)。最大尿流率下降,最大尿道外压、最大尿道闭合压和腹腔漏尿点压力治疗后升高(P<0.01或P<0.05);而最大膀胱测量容量和功能性尿道长度治疗前后无显著差异(P>0.05)。结论:米多君治疗女性SUI有效,其尿动力学原理为提高尿道的闭合压力。 AIM:To investigate the clinical efficacy and urodynamic changes of midodrine in treatment of female stress urinary incontinence (SUI). METHODS: Nineteen female patients with SUI were given midodrine 2.5 mg, thrice daily for a course of 4 wk. The involved data of urodynamics, urinary stress, incontinence clinical level scores (MHU) and self-ratings (ICIQ) were collected before and after treatment. RESULTS: After treatment, the clinical total efficacy rate reached 74 % (14/19)with decrease of the ICIQ and MHU scores significantly ( P 〈 0.01 ). MaxPura, MaxPclo and SLPP were increased ( P 〈 0.05 ) , but no significant differences occured in MCC and functional profile length (FPL) before and after the treatment( P 〉 0.05 ). CONCLUSION : Midodfine is effective in treatment for female SUI due to increasing urethral closure pressure.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2005年第11期900-902,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 米多君 尿失禁 压力性 药物疗法 尿动力学 midodrine urinary incontinence,stress drug therapy urodynamics
  • 引文网络
  • 相关文献

参考文献5

二级参考文献28

  • 1金锡御.尿失禁[A].见:金锡御 宋波 主编.临床尿动力学[C].北京:人民卫生出版社,2002.193—208.
  • 2[1]JORDAN J, SHANNON JR, BIAGGIONI L, et al. Contrasting actions of pressor agents in severe autonomic failure[J]. AM J Med, 1998, 105(2):116-124..
  • 3[2]LOW PA, GILDEN JL, FREEMAN R, et al. Efficacy of midodrine vs placebo in neurogenenic orthostatic hypotension: A randomized double-blind multicenter study[J]. JAMA, 1997, 277(13):1046-1051.
  • 4[3]PUCHMAYER V, HERDOVA J, KREJCOVA H, et al. Midodrine, a new therapeutic agent: recent experience[J]. Int Angiol, 1993, 12(2):113-118.
  • 5[4]FOUAD-TARAZI FM, OKABE M, GOREN H. Alpha-sympathomimetic treatment of autonomic insuffciency with orthostatic hypotension[J]. Am J Med, 1995, 99(6):604-610.
  • 6[5]BLOWEY DL, BALFE JW, GUPTA I, et al. Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension[J]. Am J Kidney Dis, 1996, 28(1):132-136.
  • 7[6]FLYNN JJ, MITCHELL MC, CARUSO FS, et al. Midodrine treatment for patients with hemodialysis hypotension[J]. Clin Nephrol, 1996, 45(4):261-267.
  • 8[7]LIM PS, YANG CC, LI HP, et al. Midodrine for treatment of intradialytic hypotension[J]. Nephon, 1997, 77(3):279-283.
  • 9[8]CRUZ DN, MAHNENSMITH RL, BRICK HM, et al. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up[J]. Clin Nephrol, 1998, 50(2):101-107.
  • 10[9]WARD CR, GRAY JC, GILROY JJ, et al. Midodrine: a role in the management of neurocardiogenetic syncope[J]. Heart, 1998, 79(1):45-49.

共引文献55

同被引文献54

引证文献4

二级引证文献60

;
使用帮助 返回顶部